Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms.

Cameli, P., Bergantini, L., D'Alessandro, M., Perruzza, M., Cekorja, B., Perillo, F., et al. (2020). A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1-7-7 [10.1159/000507996].

A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting

Cameli, Paolo;Bergantini, Laura;d'Alessandro, Miriana;Massa, Evaluna;Ruzza, Annamaria;Beltrami, Valerio;Sestini, Piersante;Bargagli, Elena
2020-01-01

Abstract

Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms.
2020
Cameli, P., Bergantini, L., D'Alessandro, M., Perruzza, M., Cekorja, B., Perillo, F., et al. (2020). A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1-7-7 [10.1159/000507996].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1111166
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo